What was the price per share for the 290,000 MAINZ BIOMED (MYNZ) shares granted?

The 290,000 Ordinary Shares granted to William J. Caragol had a transaction price of $0.00 per share. The footnotes clarify that the award was a grant of restricted shares with no cash consideration paid under the 2025 Omnibus Incentive Plan.

Was the MAINZ BIOMED (MYNZ) CFO’s 290,000-share award a market purchase?

No. The 290,000 Ordinary Shares were granted as an equity award, not purchased in the market. The transaction price per share was $0.00, and the footnote specifies there was no cash consideration for this restricted share grant.

CFO of MAINZ BIOMED (MYNZ) receives 290,000-share equity award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Caragol William J reported acquisition or exercise transactions in this Form 4 filing.

MAINZ BIOMED N.V. Chief Financial Officer William J. Caragol received a grant of 290,000 Ordinary Shares on February 13, 2026 as an equity award. The shares were granted at a price of $0.00 per share under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan, with no cash consideration paid.

Following this award, Caragol directly owns a total of 367,899 Ordinary Shares. A separate footnote notes that 77,899 employee stock options were previously granted and reported on a Form 3 filed January 26, 2026.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Caragol William J

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	290,000	$0.00	--

Holdings After Transaction: Ordinary Shares — 367,899 shares (Direct)

Footnotes (1)

Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid. 77,899 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026.

Form 4 Insider Transactions: What Each Field Means →

02/19/2026 - 05:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Caragol William J

(Last)

(First)

(Middle)

MAINZ BIOMED N.V.

ROBERT KOCH STRASSE 50

(Street)

MAINZ

55129

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
MAINZ BIOMED N.V. [ MYNZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	02/13/2026		A		290,000	A	$0⁽¹⁾	367,899⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid.

2. 77,899 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026.

	/s/ William Caragol	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MAINZ BIOMED (MYNZ) report for William J. Caragol?

MAINZ BIOMED reported that Chief Financial Officer William J. Caragol received a grant of 290,000 Ordinary Shares on February 13, 2026. This was an equity award under the 2025 Omnibus Incentive Plan with no cash consideration paid by Caragol.

How many MAINZ BIOMED (MYNZ) shares does William J. Caragol own after this grant?

After the equity award, William J. Caragol directly owns 367,899 Ordinary Shares of MAINZ BIOMED. This total reflects his holdings immediately following the February 13, 2026 grant of 290,000 restricted shares reported in the Form 4 filing.

Under which plan were the MAINZ BIOMED (MYNZ) shares granted to the CFO?

The shares were granted under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan. The filing’s footnote states that 290,000 restricted shares were awarded pursuant to this plan and that no cash consideration was paid in connection with the grant.

Does the MAINZ BIOMED (MYNZ) Form 4 mention any prior equity awards for William J. Caragol?

Yes. A footnote explains that 77,899 employee stock options had been granted previously and were already reported on a Form 3 filed January 26, 2026. This provides context on earlier option awards separate from the new share grant.